JCHOR
Journal of Current Hematology & Oncology Research

The Journal of Current Hematology & Oncology Research regularly publishes internationally qualified research in hematology and oncology within the current scholarly knowledge.

ISSN: Active
eISSN: 2980-0854
Creative Commons CC BY-NC-ND 4.0 International License.
EndNote Style

Online Manuscript System

Index
Original Article
Impact of immunoglobulin subtype on the frequency and severity of renal failure in multiple myeloma: a real-world retrospective study
Abstract
Aims: The aim of this study was to evaluate the association between immunoglobulin subtypes and the development of renal failure in patients with multiple myeloma.
Methods: This retrospective cross-sectional observational study included 52 patients diagnosed with multiple myeloma between January 2020 and May 2025. Patients were classified according to immunoglobulin subtype (IgG, IgA, and light chain). Renal failure was defined as an estimated glomerular filtration rate <60 mL/min/1.73 m² and/or the presence of acute kidney injury at diagnosis, according to KDIGO criteria. Clinical, laboratory, and treatment-related data were obtained from electronic medical records. Statistical analyses were performed using appropriate parametric and non-parametric tests.
Results: The mean age of the patients was 66.2 ± 10 years, and 57.7% were male. Renal failure was observed in 13.5% of patients. A significant association was found between advanced disease stage and renal failure (p = 0.006). Immunoglobulin subtype was also significantly associated with renal failure (p = 0.04), with a higher incidence observed in patients with lambda light chain disease. No significant associations were found between renal failure and other clinical or laboratory parameters.
Conclusion: Immunoglobulin subtype, particularly light chain disease, is associated with the development of renal failure in multiple myeloma. These findings highlight the importance of disease biology in renal involvement and support early diagnosis and appropriate treatment strategies to improve renal outcomes.

Keywords : Plasma cell neoplasms, kidney impairment, free light chains, disease severity, prognosis

Download Article


1. Dimopoulos MA, Merlini G, Bridoux F, et al. Management of multiple myeloma-related renal impairment: recommendations from the International Myeloma Working Group. Lancet Oncol. 2023;24(7): e293-e311. doi:10.1016/S1470-2045(23)00223-1
2. Bridoux F, Leung N, Belmouaz M, et al. Management of acute kidney injury in symptomatic multiple myeloma. Kidney Int. 2021;99(3):570-580. doi:10.1016/j.kint.2020.11.010
3. Markovic U, Romano A, Bellofiore C, et al. Role of serum free light chain assay in relapsed/refractory multiple myeloma: a real-life unicentric retrospective study. Cancers (Basel). 2021;13(19):4905. doi: 10.3390/cancers13236017
4. Leung N, Rajkumar SV. Multiple myeloma with acute light chain cast nephropathy. Blood Cancer J. 2023;13(1):46. doi:10.1038/s41408-023-00806-w
5. Terpos E, Christoulas D, Kastritis E, et al. The CKD-EPI cystatin C equation has independent prognostic value for overall survival in newly diagnosed multiple myeloma. Eur J Haematol. 2013;91(4):347-355. doi: 10.1111/ejh.12164
6. Courant M, Orazio S, Monnereau A, Preterre J, Combe C, Rigothier C. Incidence, prognostic impact and clinical outcomes of renal impairment in patients with multiple myeloma: a population-based registry. Nephrol Dial Transplant. 2021;36(3):482-490. doi:10.1093/ndt/gfz211
7. Dimopoulos MA, Sonneveld P, Leung N, et al. International Myeloma Working Group recommendations for the diagnosis and management of myeloma-related renal impairment. J Clin Oncol. 2016;34(13):1544-1557. doi:10.1200/JCO.2015.65.0044
8. Stefan G, Cinca S, Chiriac C, et al. Multiple myeloma and kidney impairment at diagnosis: a nephrological perspective from an Eastern European country. Medicina (Kaunas). 2023;59(7):1326. doi:10.3390/medicina59071326
9. Yigenoglu TN, Basci S, Bakirtas M. The value of International Staging System in predicting survival of multiple myeloma patients with renal failure. Turk J Haematol. 2020;37(3):180-186.
10. Yadav P, Cockwell P, Cook M, et al. Serum free light chain levels and renal function at diagnosis in patients with multiple myeloma. BMC Nephrol. 2018;19(1):178. doi:10.1186/s12882-018-0962-x
11. Lan M, Guo Y, Wang C, et al. Lambda light chain-restricted non-crystalline proximal tubulopathy with cast nephropathy in multiple myeloma: a case report and literature review. BMC Nephrol. 2024;25(1): 324. doi:10.1186/s12882-024-03721-9
12. Qin X, Xu Y, An G, et al. Impact of renal function on prognostic value of ß2-microglobulin in multiple myeloma: analysis of 666 patients. Zhonghua Xue Ye Xue Za Zhi. 2015;36(5):393-397. doi:10.3760/cma.j. issn.0253-2727.2015.05.008
13. Antlanger M, Dust T, Reiter T, et al. Impact of renal impairment on outcomes after autologous stem cell transplantation in multiple myeloma: a multicenter retrospective cohort study. BMC Cancer. 2018; 18(1):1008. doi:10.1186/s12885-018-4926-0
14. Sathick IJ, Drosou ME, Leung N. Myeloma light chain cast nephropathy: a review. J Nephrol. 2019;32(2):189-198. doi:10.1007/s40620-018-0492-4
15. Park S, Han B, Kim K, et al. Renal insufficiency in newly diagnosed multiple myeloma: analysis according to IMWG consensus statement. Anticancer Res. 2014;34(8):4299-4306.
16. Albagoush SA, Shumway C, Azevedo AM. Multiple myeloma. In: StatPearls. Treasure Island, FL: StatPearls Publishing; 2025.
17. Heybeli C, De Simone E, Leung N. The role of extracorporeal therapy in light chain cast nephropathy. Am J Nephrol. 2026;57(2):223-234. doi:10. 1159/000547342
Article available in :
Volume 4, Issue 2, 2026
Page : 57-62
https://doi.org/10.51271/JCHOR-0083
Article Information
Received : 06 Nis 2026
Accepted : 13 May 2026
Published : 18 May 2026
Corresponding Author :

Aslı Odabaşı Giden: Department of Hematology, Ordu State Hospital, Ordu, Turkiye

[email protected]
Citation : Odabaşı Giden A. Impact of immunoglobulin subtype on the frequency and severity of renal failure in multiple myeloma: a real-world retrospective study. J Curr Hematol Oncol Res. 2026;4(2):57-62. doi:10.51271/JCHOR-0083

Read: 62
Download : 39
Cited: 0
_Footer